NCT00622765View on ClinicalTrials.gov

A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

321

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

ObesityNutritional and Metabolic DiseasesMetabolic DiseasesNutrition DisordersOverweight

Interventions

DRUG

placebo

Placebo capsule twice daily

DRUG

R256918

5 mg capsule twice daily

DRUG

R256918

10 mg capsule twice daily

DRUG

R256918

15 mg capsule twice daily

Trial Locations (18)

Unknown

Edegem

Liège

Frederiksberg C N/A

Hellerup

Vipperroed

Helsinki

Kuopio

Berlin

Dresden

Heidelberg

Amsterdam

Hilversum

Rotterdam

Gothenburg

Huddinge

Liverpool

London

Luton

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00622765 - A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients | Biotech Hunter | Biotech Hunter